查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1424092

鸦片类药物引起的便秘市场、份额、规模、趋势、行业分析报告：活性成分、处方类型、给药途径、分销渠道、地区、细分市场预测，2024-2032

Opioid Induced Constipation Market Share, Size, Trends, Industry Analysis Report, By Active Ingredients; By Prescription Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，到 2032 年，全球鸦片类药物引起的便秘市场规模预计将达到 39.3 亿美元。 该研究报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

鸦片类药物最常用于缓解疼痛，包括吗啡、曲马多和芬太尼。 零售商店和线上电子商务平台上止痛药供应的增加对市场上鸦片类药物的需求产生了积极影响，包括鸦片类药物引起的便秘的巨大增长潜力。

製药公司、政府和非政府组织不断进行的宣传活动对鸦片类药物引起的便秘市场产生了积极影响。 例如，2023 年，製药商 Salix Pharmaceuticals 与另外两个非营利组织一起宣布 12 月 5 日为鸦片类药物引起的便秘意识日，以消除围绕这一问题的耻辱。

由于许多消费者越来越多地使用鸦片类药物，预计对鸦片类药物引起的便秘治疗的需求将会增加。 现有数据表明，服用鸦片类药物但未患癌症的人中，约有 40% 至 60% 患有鸦片类药物引起的便秘 (OIC)。

与服用鸦片类药物相关的便秘的高风险以及越来越多的研究考虑潜在原因和适当的治疗方法正在扩大市场成长机会。 例如，国家医学图书馆发表的一项研究调查了鸦片类药物引起的便秘，并考虑了治疗该疾病的潜在治疗和非治疗方法。

此外，鸦片类药物的使用可能与癌症患者增加使用鸦片类药物来缓解疼痛有关。 据製药专家称，大约 60% 至 90% 服用鸦片类药物治疗癌症的患者患有鸦片类药物引起的便秘。 鸦片类药物引起的便秘患者在日常生活活动中可能会面临更多困难，尤其是那些面临癌症疼痛的患者。

此外，研究工作正在积极影响为鸦片类药物引起的便秘患者开发有效的治疗方法。 例如，2024 年的一项研究重点在于确定鸦片类药物引起的便秘与大鼠结肠丛中 P2Y1 受体之间的关係。

鸦片类药物引起的便秘市场报告亮点

纳洛昔醇类别预计将以最快的速度成长，因为它具有治疗鸦片类药物引起的便秘的潜力。

由于医师咨询的重要性日益增加，处方药领域占了最大份额。

口服药物在市场上占据主导地位，主要是因为治疗摄取方便且疗效高。

由于老年人口比例较大，亚太地区预计将出现最快的成长速度。

目录

第 1 章简介

第 2 章执行摘要

第 3 章研究方法

第 4 章洞察全球鸦片类药物引起的便秘市场

  • 鸦片类药物引起的便秘 - 行业快照
  • 鸦片类药物引起的便秘市场动态
    • 促进因素和机会
      • 老年人的存在
      • 鸦片类药物处方显着增加
    • 抑制因素和挑战
      • 减少市面上鸦片类药物的使用
  • PESTLE分析
  • 鸦片类药物引起的便秘产业趋势
  • 价值链分析
  • COVID-19 感染的影响分析

第 5 章全球鸦片类药物引起的便秘市场：依活性成分划分

  • 主要发现
  • 简介
  • 纳洛昔康
  • 鲁比前列酮
  • 溴化甲基纳曲酮
  • 多库酯钠
  • 其他

第 6 章全球鸦片类药物引起的便秘市场（依处方类型）

  • 主要发现
  • 简介
  • 非处方药
  • 处方、自然疗法

第 7 章全球鸦片类药物引起的便秘市场（依给药途径）

  • 主要发现
  • 简介
  • 口服
  • 注射用
  • 其他

第 8 章全球鸦片类药物引起的便秘市场（依通路）

  • 主要发现
  • 简介
  • 医院药房
  • 网路药局
  • 零售药局

第 9 章全球鸦片类药物引起的便秘市场（按地区）

  • 主要发现
  • 简介
    • 2019-2032 年鸦片类药物引起的便秘市场评估，各地区
  • 鸦片类药物引起的便秘市场 - 北美
    • 北美：2019-2032 年鸦片类药物引起的便秘市场（依活性成分）
    • 北美：鸦片类药物引起的便秘市场，依分销管道划分，2019-2032 年
    • 北美：2019-2032 年鸦片类药物引起的便秘市场（依处方型）
    • 北美：鸦片类药物引起的便秘市场，依给药途径划分，2019-2032 年
    • 鸦片类药物引起的便秘市场 - 美国
    • 鸦片类药物引起的便秘市场 - 加拿大
  • 鸦片类药物引起的便秘市场 - 欧洲
    • 欧洲：鸦片类药物引起的便秘市场（依活性成分），2019-2032 年
    • 欧洲：鸦片类药物引起的便秘市场，依分销管道划分，2019-2032 年
    • 欧洲：鸦片类药物引起的便秘市场（依处方类型），2019-2032 年
    • 欧洲：鸦片类药物引起的便秘市场，依给药途径划分，2019-2032 年
    • 鸦片类药物引起的便秘市场 - 英国
    • 鸦片类药物引起的便秘市场 - 法国
    • 鸦片类药物引起的便秘市场 - 德国
    • 鸦片类药物引起的便秘市场 - 义大利
    • 鸦片类药物引起的便秘市场 - 西班牙
    • 鸦片类药物引起的便秘市场 - 荷兰
    • 鸦片类药物引起的便秘市场 - 俄罗斯
  • 鸦片类药物引起的便秘市场 - 亚太地区
    • 亚太地区：2019-2032 年鸦片类药物引起的便秘市场（依活性成分）
    • 亚太地区：鸦片类药物引起的便秘市场，依通路划分，2019-2032 年
    • 亚太地区：2019-2032 年鸦片类药物引起的便秘市场（依处方类型）
    • 亚太地区：2019-2032 年鸦片类药物引起的便秘市场（依给药途径）
    • 鸦片类药物引起的便秘市场 - 中国
    • 鸦片类药物引起的便秘市场 - 印度
    • 鸦片类药物引起的便秘市场 - 日本
    • 鸦片类药物引起的便秘市场 - 马来西亚
    • 鸦片类药物引起的便秘市场 - 印度尼西亚
    • 鸦片类药物引起的便秘市场 - 韩国
  • 鸦片类药物引起的便秘市场 - 中东和非洲
    • 中东和非洲：鸦片类药物引起的便秘市场（按活性成分），2019-2032 年
    • 中东和非洲：鸦片类药物引起的便秘市场，按分销管道划分，2019-2032 年
    • 中东和非洲：2019-2032 年鸦片类药物引起的便秘市场（按处方类型）
    • 中东和非洲：2019-2032 年鸦片类药物引起的便秘市场（依给药途径）
    • 鸦片类药物引起的便秘市场 - 沙乌地阿拉伯
    • 鸦片类药物引起的便秘市场 - 南非
    • 鸦片类药物引起的便秘市场 - 以色列
    • 鸦片类药物引起的便秘市场 - 阿拉伯联合大公国
  • 鸦片类药物引起的便秘市场 - 拉丁美洲
    • 拉丁美洲：鸦片类药物引起的便秘市场（依活性成分），2019-2032 年
    • 拉丁美洲：鸦片类药物引起的便秘市场，按分销管道划分，2019-2032 年
    • 拉丁美洲：2019-2032 年鸦片类药物引起的便秘市场（以处方类型）
    • 拉丁美洲：2019-2032 年鸦片类药物引起的便秘市场（依给药途径）
    • 鸦片类药物引起的便秘市场 - 墨西哥
    • 鸦片类药物引起的便秘市场 - 巴西
    • 鸦片类药物引起的便秘市场 - 阿根廷

第 10 章竞争态势

  • 扩张与收购分析
    • 扩大
    • 收购
  • 伙伴关係/协作/协议/揭露

第 11 章公司简介

  • Abbott（US）
  • Aurobindo Pharma（India）
  • Bayer AG（Germany）
  • Boehringer Ingelheim International GmbH.（Germany）
  • Bristol Myers Squibb Company（US）
  • Cosmo Pharmaceuticals（Ireland）
  • Daewoong Pharmaceutical Company（South Korea）
  • F. Hoffmann-La Roche Ltd（Switzerland）
  • Fresenius Kabi AG（Germany）
  • GSK Plc.（UK）
  • Hikma Pharmaceuticals PLC（UK）
  • Merck & Co Inc.（US）
  • Mylan NV（US）
  • Novartis AG（Switzerland）
  • Pfizer Inc（US）
Product Code: PM4344

The global opioid induced constipation market size is expected to reach USD 3.93 billion by 2032, according to a new study by Polaris Market Research. The report "Opioid Induced Constipation Market Share, Size, Trends, Industry Analysis Report, By Active Ingredients; By Prescription Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Opioids are most used to get relief from pain, as they include morphine, tramadol, and fentanyl. The increased accessibility of painkillers at retail and online e-commerce platforms is showing a positive impact on the demand for opioids in the marketplace, including significant growth potential for opioid-induced constipation.

The rising awareness campaigns by pharmaceutical companies, governments, and non-government agencies are demonstrating a positive impact on the opioid-induced constipation market. For instance, in 2023, Salix Pharmaceuticals, a drug manufacturer, along with the other two non-profit organisations, declared December 5 as the opioid-induced constipation awareness day to confront the stigmas surrounding the issue.

The rising use of opioids among the larger consumer base is expected to boost demand for opioid-induced constipation treatment. According to the available data, among the individuals who consumed opioids without cancer, around 40-60% of the people get opioid-induced constipation (OIC).

The higher risk of constipation with the intake of opioid-related drugs, along with the growing research studies to review the potential causes and suitable treatments, are showing wider growth opportunities for the market. For instance, a study published in the National Library of Medicine explored opioid-induced constipation and reviewed potential therapeutic and non-therapeutic treatments to treat the disease.

Furthermore, the use of opioids can be related to the rising use by cancer patients to get pain relief. According to pharmaceutical experts, approximately 60 to 90% of patients who took the opioid for cancer treatment suffered from opioid-induced constipation. Opioid-induced constipation patients are likely to face more difficulties in day-to-day life activities, primarily those facing cancer pain.

Moreover, research activities are positively influencing the creation of effective treatments for patients suffering from opioid-induced constipation. For instance, a 2024 study focused on finding the relationship between opioid-induced constipation and the P2Y1 receptor in the colonic myenteric plexus of rats.

Opioid Induced Constipation Market Report Highlights

Naloxegol segment will grow at the fastest pace, due to its potential for treating opioid induced constipation issues.

Prescription segment held the largest share, owing to the rising importance of doctor consultation.

Oral segment dominated the market, primarily due to its ease of treatment intake and higher effectiveness.

Asia Pacific will register the fastest pace, attributable to the presence of the large proportion of elderly population.

The global players include Abbott, Aurobindo Pharma, Bayer, Boehringer Ingelheim International, & Bristol Myers Squibb Company.

Polaris Market Research has segmented the opioid induced constipation market report based on active ingredients, prescription type, route of administration, distribution channel and region:

Opioid Induced Constipation, Active Ingredients Outlook (Revenue - USD Billion, 2019 - 2032)

  • Naloxegol
  • Lubiprostone
  • Methylnaltrexone Bromide
  • Docusate Sodium
  • Others

Opioid Induced Constipation, Prescription Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Over The Counter Medicines
  • Prescription, Natural Remedies

Opioid Induced Constipation, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Oral
  • Injectable
  • Others

Opioid Induced Constipation, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Opioid Induced Constipation, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Opioid Induced Constipation Market Insights

  • 4.1. Opioid Induced Constipation - Industry Snapshot
  • 4.2. Opioid Induced Constipation Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. The presence of an elderly population
      • 4.2.1.2. The significant rise in opioid prescriptions
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. The declining use of opioids in the marketplace
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Opioid Induced Constipation Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Opioid Induced Constipation Market, by Active Ingredients

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • 5.3. Naloxegol
    • 5.3.1. Global Opioid Induced Constipation Market, by Naloxegol, by Region, 2019-2032 (USD Billion)
  • 5.4. Lubiprostone
    • 5.4.1. Global Opioid Induced Constipation Market, by Lubiprostone, by Region, 2019-2032 (USD Billion)
  • 5.5. Methylnaltrexone Bromide
    • 5.5.1. Global Opioid Induced Constipation Market, by Methylnaltrexone Bromide, by Region, 2019-2032 (USD Billion)
  • 5.6. Docusate Sodium
    • 5.6.1. Global Opioid Induced Constipation Market, by Docusate Sodium, by Region, 2019-2032 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Opioid Induced Constipation Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Opioid Induced Constipation Market, by Prescription Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • 6.3. Over The Counter Medicines
    • 6.3.1. Global Opioid Induced Constipation Market, by Over The Counter Medicines, by Region, 2019-2032 (USD Billion)
  • 6.4. Prescription, Natural Remedies
    • 6.4.1. Global Opioid Induced Constipation Market, by Prescription, Natural Remedies, by Region, 2019-2032 (USD Billion)

7. Global Opioid Induced Constipation Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • 7.3. Oral
    • 7.3.1. Global Opioid Induced Constipation Market, by Oral, by Region, 2019-2032 (USD Billion)
  • 7.4. Parenteral
    • 7.4.1. Global Opioid Induced Constipation Market, by Parenteral, by Region, 2019-2032 (USD Billion)
  • 7.5. Others
    • 7.5.1. Global Opioid Induced Constipation Market, by Others, by Region, 2019-2032 (USD Billion)

8. Global Opioid Induced Constipation Market, by Distribution Channel

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.3. Hospital Pharmacy
    • 8.3.1. Global Opioid Induced Constipation Market, by Hospital Pharmacy, by Region, 2019-2032 (USD Billion)
  • 8.4. Online Pharmacy
    • 8.4.1. Global Opioid Induced Constipation Market, by Online Pharmacy, by Region, 2019-2032 (USD Billion)
  • 8.5. Retail Pharmacy
    • 8.5.1. Global Opioid Induced Constipation Market, by Retail Pharmacy, by Region, 2019-2032 (USD Billion)

9. Global Opioid Induced Constipation Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Opioid Induced Constipation Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 9.3. Opioid Induced Constipation Market - North America
    • 9.3.1. North America: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
    • 9.3.2. North America: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.3.3. North America: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
    • 9.3.4. North America: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.3.5. Opioid Induced Constipation Market - U.S.
      • 9.3.5.1. U.S.: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.3.5.2. U.S.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.5.3. U.S.: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.3.5.4. U.S.: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.3.6. Opioid Induced Constipation Market - Canada
      • 9.3.6.1. Canada: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.3.6.2. Canada: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.6.3. Canada: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.3.6.4. Canada: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.4. Opioid Induced Constipation Market - Europe
    • 9.4.1. Europe: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
    • 9.4.2. Europe: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.3. Europe: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
    • 9.4.4. Europe: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.5. Opioid Induced Constipation Market - UK
      • 9.4.5.1. UK: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.5.2. UK: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.5.3. UK: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.5.4. UK: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.6. Opioid Induced Constipation Market - France
      • 9.4.6.1. France: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.6.2. France: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.6.3. France: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.6.4. France: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.7. Opioid Induced Constipation Market - Germany
      • 9.4.7.1. Germany: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.7.2. Germany: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.7.3. Germany: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.7.4. Germany: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.8. Opioid Induced Constipation Market - Italy
      • 9.4.8.1. Italy: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.8.2. Italy: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.8.3. Italy: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.8.4. Italy: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.9. Opioid Induced Constipation Market - Spain
      • 9.4.9.1. Spain: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.9.2. Spain: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.9.3. Spain: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.9.4. Spain: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.10. Opioid Induced Constipation Market - Netherlands
      • 9.4.10.1. Netherlands: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.10.2. Netherlands: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.10.3. Netherlands: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.10.4. Netherlands: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.11. Opioid Induced Constipation Market - Russia
      • 9.4.11.1. Russia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.11.2. Russia.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.11.3. Russia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.11.4. Russia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.5. Opioid Induced Constipation Market - Asia Pacific
    • 9.5.1. Asia Pacific: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
    • 9.5.2. Asia Pacific: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.3. Asia Pacific: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
    • 9.5.4. Asia Pacific: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.5. Opioid Induced Constipation Market - China
      • 9.5.5.1. China: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.5.2. China.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.5.3. China: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.5.4. China: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.6. Opioid Induced Constipation Market - India
      • 9.5.6.1. India: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.6.2. India.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.6.3. India: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.6.4. India: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.7. Opioid Induced Constipation Market - Japan
      • 9.5.7.1. Japan: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.7.2. Japan.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.7.3. Japan: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.7.4. Japan: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.8. Opioid Induced Constipation Market - Malaysia
      • 9.5.8.1. Malaysia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.8.2. Malaysia.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.8.3. Malaysia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.8.4. Malaysia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.9. Opioid Induced Constipation Market - Indonesia
      • 9.5.9.1. Indonesia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.9.2. Indonesia.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.9.3. Indonesia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.9.4. Indonesia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.10. Opioid Induced Constipation Market - South Korea
      • 9.5.10.1. South Korea: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.10.2. South Korea.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.10.3. South Korea: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.10.4. South Korea: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.6. Opioid Induced Constipation Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
    • 9.6.2. Middle East & Africa: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.3. Middle East & Africa: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
    • 9.6.4. Middle East & Africa: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.6.5. Opioid Induced Constipation Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.6.6. Opioid Induced Constipation Market - South Africa
      • 9.6.6.1. South Africa: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.6.6.2. South Africa: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.6.3. South Africa: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.6.6.4. South Africa: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.6.7. Opioid Induced Constipation Market - Israel
      • 9.6.7.1. Israel: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.6.7.2. Israel: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.7.3. Israel: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.6.7.4. Israel: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.6.8. Opioid Induced Constipation Market - UAE
      • 9.6.8.1. UAE: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.6.8.2. UAE: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.8.3. UAE: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.6.8.4. UAE: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.7. Opioid Induced Constipation Market - Latin America
    • 9.7.1. Latin America: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
    • 9.7.2. Latin America: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.3. Latin America: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
    • 9.7.4. Latin America: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.7.5. Opioid Induced Constipation Market - Mexico
      • 9.7.5.1. Mexico: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.7.5.2. Mexico: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.5.3. Mexico: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.7.5.4. Mexico: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.7.6. Opioid Induced Constipation Market - Brazil
      • 9.7.6.1. Brazil: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.7.6.2. Brazil: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.6.3. Brazil: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.7.6.4. Brazil: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.7.7. Opioid Induced Constipation Market - Argentina
      • 9.7.7.1. Argentina: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.7.7.2. Argentina: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.7.3. Argentina: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.7.7.4. Argentina: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Abbott (US)
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Aurobindo Pharma (India)
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Bayer AG (Germany)
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Boehringer Ingelheim International GmbH. (Germany)
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Bristol Myers Squibb Company (US)
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Cosmo Pharmaceuticals (Ireland)
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Daewoong Pharmaceutical Company (South Korea)
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. F. Hoffmann-La Roche Ltd (Switzerland)
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Fresenius Kabi AG (Germany)
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. GSK Plc. (UK)
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Hikma Pharmaceuticals PLC (UK)
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Merck & Co Inc. (US)
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13. Mylan NV (US)
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Novartis AG (Switzerland)
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
  • 11.15. Pfizer Inc (US)
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Benchmarking
    • 11.15.4. Recent Development

List of Tables

  • Table 1 Global Opioid Induced Constipation Market, by Active Ingredients, by Region, 2019-2032 (USD Billion)
  • Table 2 Global Opioid Induced Constipation Market, by Prescription Type, by Region, 2019-2032 (USD Billion)
  • Table 3 Global Opioid Induced Constipation Market, by Route of Administration, by Region, 2019-2032 (USD Billion)
  • Table 4 Global Opioid Induced Constipation Market, by Distribution Channel, by Region, 2019-2032 (USD Billion)
  • Table 5 Opioid Induced Constipation Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 6 North America: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 7 North America: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 8 North America: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 9 North America: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 10 U.S.: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 11 U.S.: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 12 U.S.: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 13 U.S.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 14 Canada: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 15 Canada: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 16 Canada: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 17 Canada: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 18 Europe: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 19 Europe: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 20 Europe: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 21 Europe: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 22 Germany: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 23 Germany: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 25 Germany: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 26 France: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 27 France: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 28 France: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 29 France: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 30 UK: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 31 UK: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 32 UK: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 33 UK: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 34 Italy: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 35 Italy: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 36 Italy: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 37 Italy: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 38 Netherlands: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 39 Netherlands: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 40 Netherlands: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 41 Netherlands: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 42 Spain: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 43 Spain: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 44 Spain: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 45 Spain: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 46 Russia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 47 Russia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 48 Russia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 49 Russia: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 50 Asia Pacific: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 51 Asia Pacific: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 52 Asia Pacific: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 53 Asia Pacific: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 54 China: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 55 China: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 56 China: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 57 China: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 58 Japan: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 59 Japan: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 60 Japan: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 61 Japan: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 62 India: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 63 India: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 64 India: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 65 India: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 66 Indonesia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 67 Indonesia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 68 Indonesia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 69 Indonesia: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 70 Malaysia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 71 Malaysia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 72 Malaysia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 73 Malaysia: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 74 South Korea: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 75 South Korea: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 76 South Korea: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 77 South Korea: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 78 Latin America: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 79 Latin America: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 80 Latin America: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 81 Latin America: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 82 Brazil: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 83 Brazil: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 84 Brazil: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 85 Brazil: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 86 Mexico: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 87 Mexico: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 88 Mexico: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 89 Mexico: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 90 Argentina: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 91 Argentina: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 92 Argentina: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 93 Argentina: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 94 Middle East & Africa: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 95 Middle East & Africa: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 96 Middle East & Africa: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 97 Middle East & Africa: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 98 UAE: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 99 UAE: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 100 UAE: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 101 UAE: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 102 Saudi Arabia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 103 Saudi Arabia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 104 Saudi Arabia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 105 Saudi Arabia: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 106 South Africa: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 107 South Africa: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 108 South Africa: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 109 South Africa: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 110 Israel: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 111 Israel: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 112 Israel: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 113 Israel: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Opioid Induced Constipation Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Distribution Channel
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Active Ingredients
  • Figure 7. Global Opioid Induced Constipation Market, by Active Ingredients, 2021 & 2030 (USD Billion)
  • Figure 8. Market by Distribution Channel
  • Figure 9. Global Opioid Induced Constipation Market, by Distribution Channel, 2021 & 2030 (USD Billion)
  • Figure 10. Market by Prescription Type
  • Figure 11. Global Opioid Induced Constipation Market, by Prescription Type, 2021 & 2030 (USD Billion)
  • Figure 12. Market by Route of Administration
  • Figure 13. Global Opioid Induced Constipation Market, by Route of Administration, 2021 & 2030 (USD Billion)